Key Points
- Director sale: Tempus AI director David Epstein sold 250 shares on June 1 for about $12,350 at an average price of $49.40. The transaction was made under a pre-arranged Rule 10b5-1 plan.
- Stock and earnings backdrop: TEM traded down 4.3% and opened at $47.51, with the stock well below its 52-week high of $104.32. The company recently beat earnings expectations, reporting a smaller-than-expected loss and 36.1% year-over-year revenue growth.
- Wall Street view: Analysts remain mixed, with nine Buy ratings, four Holds, and two Sells. The consensus rating is Hold, and the average price target is $68.64.
Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) Director David Epstein sold 250 shares of the firm's stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $49.40, for a total transaction of $12,350.00. Following the completion of the sale, the director owned 31,464 shares in the company, valued at $1,554,321.60. This represents a 0.79% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Tempus AI Trading Down 4.3%
Shares of TEM stock opened at $47.51 on Thursday. Tempus AI, Inc. has a 12-month low of $41.73 and a 12-month high of $104.32. The company has a current ratio of 3.31, a quick ratio of 3.15 and a debt-to-equity ratio of 2.96. The firm's 50 day moving average is $48.83 and its 200 day moving average is $57.67. The stock has a market capitalization of $8.53 billion, a P/E ratio of -27.62 and a beta of 3.62.
Tempus AI (NASDAQ:TEM - Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.08. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The company had revenue of $348.12 million for the quarter, compared to analysts' expectations of $345.44 million. During the same quarter last year, the company posted ($0.24) earnings per share. The firm's quarterly revenue was up 36.1% on a year-over-year basis. Research analysts expect that Tempus AI, Inc. will post -1.35 earnings per share for the current year.
Analyst Ratings Changes
Several brokerages recently issued reports on TEM. BTIG Research restated a "buy" rating and issued a $80.00 target price on shares of Tempus AI in a report on Monday. TD Cowen raised their target price on shares of Tempus AI from $65.00 to $68.00 and gave the stock a "buy" rating in a report on Wednesday, May 6th. Morgan Stanley dropped their price target on shares of Tempus AI from $85.00 to $70.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 3rd. Guggenheim dropped their price target on shares of Tempus AI from $95.00 to $60.00 and set a "buy" rating on the stock in a research note on Monday, March 30th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Tempus AI from $80.00 to $60.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 25th. Nine analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $68.64.
Read Our Latest Research Report on Tempus AI
Institutional Trading of Tempus AI
Hedge funds and other institutional investors have recently bought and sold shares of the stock. JPL Wealth Management LLC purchased a new stake in Tempus AI in the third quarter worth about $26,000. Los Angeles Capital Management LLC purchased a new stake in Tempus AI in the fourth quarter worth about $27,000. Harvest Fund Management Co. Ltd purchased a new stake in Tempus AI in the third quarter worth about $38,000. Tsfg LLC increased its position in Tempus AI by 1,515.2% in the third quarter. Tsfg LLC now owns 533 shares of the company's stock worth $43,000 after buying an additional 500 shares in the last quarter. Finally, Danske Bank A S purchased a new stake in Tempus AI in the third quarter worth about $48,000. Hedge funds and other institutional investors own 24.22% of the company's stock.
Tempus AI Company Profile
(
Get Free Report)
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
